Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.
BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp received new equity-based compensation awards. She was granted 10,069 performance share units and options on 12,586 ordinary shares, both with no upfront purchase price. The options have an exercise price of EUR 89.38 and may be settled in shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions.
BioNTech SE submitted a Form 144 notice relating to the proposed sale of American Depositary Shares representing ordinary shares and ordinary shares, no par value. The filing lists stock option exercise dates of 11/21/2022 and 08/09/2024 and references 05/13/2026 and Nasdaq Global Select.
BioNTech SE has authorized a new share repurchase program allowing the company to buy back American Depositary Shares for an aggregate amount of up to $1.0 billion. The program runs until and including May 6, 2027 and will be funded from existing cash resources.
The repurchased ADSs are expected to be used to satisfy obligations in the ordinary course of business. BioNTech describes the program as supporting capital efficiency, long-term value creation and financial flexibility as it pursues its objective to become a multi-product company by 2030.
BioNTech reported a much weaker first quarter of 2026 as COVID-19 revenues continued to decline and investment in its oncology pipeline accelerated. Revenues fell to €118.1 million from €182.8 million a year earlier, mainly because COVID‑19 vaccine revenues dropped to €66.9 million from €133.0 million.
Heavy spending on R&D of €557.0 million, plus higher sales and marketing and general and administrative costs, led to an operating loss of €677.5 million and a net loss of €531.9 million, or €2.10 per share, compared with a €1.73 loss per share last year.
Despite the loss, BioNTech’s balance sheet remained strong, with €9,939.4 million in cash and cash equivalents and total cash, cash equivalents and security investments of €16,763.3 million as of March 31, 2026. The company plans to launch a share repurchase program of up to $1.0 billion of ADSs over the next twelve months.
BioNTech also announced a major manufacturing footprint consolidation, planning to exit operations at sites in Idar‑Oberstein, Marburg, Singapore and CureVac locations, plus wind down subsidiary JPT Peptide Technologies. These measures could affect about 2,000 positions in total and are intended to generate recurring annual cost savings by 2029 while supporting the shift toward a broader late‑stage oncology portfolio.
BioNTech SE reported a weak but strategy-heavy first quarter of 2026, as COVID-19 vaccine demand declined while oncology investments accelerated. Revenues fell to €118.1 million from €182.8 million a year earlier, driven mainly by lower COVID-19 vaccine sales. The company posted a net loss of €531.9 million (adjusted net loss €494.6 million), with diluted loss per share of €2.10 (adjusted €1.95), compared with a €415.8 million loss and €1.73 per share in 2025.
BioNTech reaffirmed its 2026 guidance, including total revenues of €2.0–2.3 billion, adjusted R&D of €2.2–2.5 billion and adjusted SG&A of €700–800 million, underscoring its continued pivot from COVID-19 to oncology. R&D spending rose to €557.0 million, largely for immuno‑oncology and antibody‑drug conjugate programs such as pumitamig and gotistobart, and for integrating the BioNTech China and CureVac acquisitions.
Liquidity remained strong, with €16.8 billion in cash, cash equivalents and security investments as of March 31, 2026, and 252,884,261 shares outstanding (excluding treasury shares. Management and the Supervisory Board expect to authorize a share repurchase program of up to $1.0 billion over twelve months. BioNTech also plans to consolidate its manufacturing footprint, exiting sites in Idar‑Oberstein, Marburg, Singapore and CureVac locations, affecting up to approximately 1,860 positions and potentially yielding about €500 million in recurring annual savings by 2029 to support oncology development.
BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares. The shares were sold at an average price of $110.5592 per share and are held through Tofino GmbH, a company of which Poetting is the sole shareholder.
After this transaction, indirect holdings reported for Poetting through Tofino GmbH total 399,387 Ordinary Shares. This filing reflects a net sale, with no option exercises or derivative transactions disclosed in this report.
BioNTech SE Chief Executive Officer Ugur Sahin filed an amended insider ownership report that updates his indirect holdings in the company. The filing shows 39,218,111 ordinary shares are held by Medine GmbH, an entity of which he is the sole shareholder.
Within this amount, 106,721 ordinary shares are held for the benefit of an individual under a trust arrangement. Medine GmbH has voting power, but not dispositive power, over those trust shares. Sahin may be deemed to beneficially own the ordinary shares held by Medine GmbH, and the amendment does not report any new purchases or sales.
BioNTech SE reported positive Phase 2 data for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan (BNT323/DB‑1303) in 145 patients with advanced or metastatic HER2‑expressing endometrial cancer whose disease had progressed after prior therapies.
The primary endpoint was met, with a confirmed objective response rate of 49.3% in 73 centrally HER2‑tested patients previously treated with checkpoint inhibitors and 47.9% in all centrally tested patients, alongside a median progression‑free survival of 8.1 months. Responses were seen across all HER2 expression levels, including lower HER2 tumors, and safety was described as manageable, with grade ≥3 treatment‑related adverse events in 46.9% of patients and grade ≥3 interstitial lung disease or pneumonitis in 4.8%. Trastuzumab pamirtecan has U.S. FDA Fast Track and Breakthrough Therapy designations for endometrial cancer, and a global Phase 3 confirmatory trial is ongoing with plans for a biologics license application in 2026, subject to regulatory feedback.
BioNTech SE has called a virtual Annual General Meeting for May 15, 2026, where shareholders will vote electronically via an Investor Portal. The meeting will present 2025 financial statements and a proposal to carry forward the EUR 6,901,677,892.10 balance sheet profit in full.
Key resolutions include expanding the Supervisory Board from six to eight members, re-electing three current members, and electing two new oncology and clinical-development specialists. Shareholders will also vote on extending authorization to hold virtual AGMs and replacing the remaining 2025 capital authorization with a new Authorized Capital 2026 of up to EUR 129,513,743 (50% of current share capital).
The agenda further covers approval of the 2025 compensation report, appointment of EY as auditor for 2026, and a domination and profit-and-loss transfer agreement with wholly owned subsidiary BioNTech Discovery GmbH. As of the notice date, share capital comprises 259,027,487 registered shares and 252,884,261 voting shares after treasury holdings.
BioNTech SE filed Amendment No. 1 to its Form 20-F to correct a typographical error in the date of EY’s audit opinions, changing them from March 10, 2025 to March 10, 2026 and updating the most recent practicable ordinary share count to 252,884,261.
The amendment does not change any financial statements or other disclosures for the year ended December 31, 2025. EY issued unqualified opinions on the consolidated IFRS financial statements and on internal control over financial reporting as of December 31, 2025.
The audited financials include €2.0 billion of collaboration revenue from COVID-19 vaccine sales, €0.6 billion of revenue from the Bristol-Myers Squibb collaboration, and business combinations such as the Biotheus and CureVac acquisitions with significant recognized intangible assets.